Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46

斯迪富维持Neurogene(NGNE.US)买入评级，上调目标价至46美元

moomoo资讯 · 11/20 22:31 · 评级/大行评级

Stifel analyst Paul Matteis maintains $Neurogene (NGNE.US)$ with a buy rating, and adjusts the target price from $44 to $46.

According to TipRanks data, the analyst has a success rate of 39.5% and a total average return of 2.2% over the past year.

AnalystRecentRatingAutoNews_84649510670731_20241120_7673f923e58a04f981f5a1c734528096eeced3ba_1732185124515892_mm_en

Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:

The stock is currently trading "near cash" following the company's disclosure of a Serious Adverse Event in its NGN-401 high dose trial, along with the termination of the Battens program. Despite these issues, management does not anticipate a clinical hold after discussions with the FDA, noting the safety of the low-dose treatment.
The revised outlook for the shares reflects a model update for the third quarter of 2024 and considerations regarding the status of a trial participant who was critically affected after receiving a high dose of NGN-401. The adjustment in expectations also accounts for a reduced forecast of the market share for the Rett syndrome gene therapy, specifically NGN-401, now estimated at 50%.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

斯迪富分析师Paul Matteis维持$Neurogene (NGNE.US)$买入评级，并将目标价从44美元上调至46美元。

根据TipRanks数据显示，该分析师近一年总胜率为39.5%，总平均回报率为2.2%。

AnalystRecentRatingAutoNews_84649510670731_20241120_7673f923e58a04f981f5a1c734528096eeced3ba_1732185124515892_mm_sc

此外，综合报道，$Neurogene (NGNE.US)$近期主要分析师观点如下：

继该公司在其 NGN-401 高剂量试验中披露严重不良事件以及终止巴顿计划之后，该股目前的交易价格为 “接近现金”。尽管存在这些问题，但管理层在与美国食品药品管理局讨论后预计不会暂停临床治疗，同时指出低剂量治疗的安全性。
修订后的股票展望反映了2024年第三季度的模型更新以及对在接受高剂量 NGN-401 后受到严重影响的试验参与者状况的考虑。预期的调整还导致对雷特综合征基因疗法（特别是 NGN-401）市场份额的预测降低，目前估计为50％。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46

风险及免责提示

声明